Northwest Permanente, P.C.

The Crunchbase Megadeals Board highlights top U.S. startup funding rounds over $100M, with biotech and healthcare leading. Notable deals include DDN's $300M for data storage, Innovaccer's $275M for healthcare AI, and Whatnot's $265M for e-commerce. Biotech firms Aviceda, Tenvie, Timberlyne, and Ouro Medicines also secured significant funding.

The NIH Pragmatic Trials Collaboratory hosts a virtual workshop on June 20-21, 2023, focusing on translating evidence from pragmatic clinical trials into health system decisions. Keynote by Andrew B. Bindman, with panels discussing evidence use, generation, faster learning, and incentives. Free, public registration required.

Doxycycline post-exposure prophylaxis (doxyPEP) significantly reduces chlamydia and syphilis in MSM and transgender women, with less impact on gonorrhea. Studies in San Francisco and Kaiser Permanente show real-world effectiveness, though questions about antibiotic resistance and gonorrhea efficacy remain.

Managed care has evolved over 30 years, focusing on prevention, quality metrics, and data analytics. Despite advancements, challenges like misinformation and short-term financial focus persist. The industry cycles through trends like corporate medicine and value-based care, with AI and personalized medicine emerging as future focuses. Trust, data utilization, and aligning incentives remain key for progress.

Rising health care costs in America, especially in Idaho, are a major concern, with prices for services and insurance premiums significantly increasing. Experts highlight the need for policy changes and competition to address affordability and quality issues, emphasizing the role of insurers, businesses, and lawmakers in finding solutions.

Tim Mok discussed balancing clinical outcomes with cost in pharmacy decision-making, emphasizing patient outcomes, provider experience, and safety. He highlighted the importance of real-world evidence for newer therapeutics and the challenges of transitioning to value-based care, stressing the need for education on cost considerations.

Grove AI raised $4.9M seed funding for clinical trial management. Cemex secured funding for lower-emission vehicles. Ault & Company increased stake in Hyperscale Data. Micron Biomedical secured $43M in grants. Innovaccer raised $275M Series F. Hippocratic AI raised $114M Series B. Evergreen Nephrology raised $130M. DDN received $300M investment. OnPay secured over $100M. Citrin Cooperman to receive investment from Blackstone. Stellar raised $2.7M seed. Alta Resource raised $5.1M seed. Sixth Street to manage $13B of Northwestern Mutual’s assets. Nassau Financial Group received $200M from Golub. Pison received funding from Samsung Ventures. Trinity Ventures closed $435M fund. Francis Medical raised $80M Series C. Pepticom raised $6.6M Series A1. Fort Partners secured $107.6M loan. Northern Light raised $23M. CourseKey received investment from PSG. Deciphex raised $32.3M Series C. FIRE1 raised $120M. Jones raised $15M Series B. XyloCor Therapeutics raised $67.5M Series B. Waterpoint Lane closed Fund I. Whatnot raised $265M Series E.

Hawaiʻi faces severe doctor shortages, especially in Maui County, exacerbated by last year's wildfires. The fires destroyed medical facilities, displaced workers, and worsened the housing crisis, prompting many medical professionals to leave. A University of Hawaiʻi report indicates Maui's physician workforce needs to grow by about 41%. High living costs and financial stress are driving doctors away, with some considering relocating to areas with lower costs. Efforts to address the shortage include building rental homes for health care workers and initiatives to encourage local youth to pursue medical careers.

The nursing shortage crisis demands urgent recruitment and thorough screening to ensure patient safety. Modern screening programs offer speed, accuracy, and cost-effectiveness, crucial for maintaining care quality amid staffing challenges.

The USPTO withdrew a proposed rule to add a new requirement for terminal disclaimers to overcome non-statutory double patenting, favoring big pharma over biosimilar developers. The decision was based on 349 comments, with big pharma's outweighing those favoring the change.